ARS Pharmaceuticals: Still A Buy As Neffy Access Improves
ARS Pharmaceuticals is enhancing access to its epinephrine nasal spray, Neffy, which is crucial for treating severe allergic reactions. The company is expanding its partnerships and sales force to improve availability by the second half of 2026. Analysts remain optimistic about the stock's potential as these efforts progress.
- ▪ARS Pharmaceuticals is focused on scaling its needle-free epinephrine spray, Neffy.
- ▪The company is working with CVS Caremark and Medicaid to improve access to Neffy.
- ▪A larger sales force is being deployed to enhance retail affordability and availability of the product.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4906897-ars-pharmaceuticals-stock-still-a-buy-as-neffy-access-improves"},"author":{"@type":"Person","name":"Myriam…
Excerpt limited to ~120 words for fair-use compliance. The full article is at All Articles on Seeking Alpha.
Discussion
0 commentsMore from All Articles on Seeking Alpha
